ID   MC/CAR
AC   CVCL_1397
SY   MC-CAR; MCCAR
DR   CLO; CLO_0007575
DR   EFO; EFO_0002229
DR   CLDB; cl5227
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-8083
DR   BioSample; SAMN03471132
DR   CCRID; 4201HUM-CCTCC00324
DR   CCTCC; GDC0324
DR   Cell_Model_Passport; SIDM00636
DR   ChEMBL-Cells; CHEMBL3308240
DR   ChEMBL-Targets; CHEMBL2366274
DR   Cosmic; 683665
DR   Cosmic; 2131565
DR   Cosmic-CLP; 683665
DR   DepMap; ACH-002270
DR   EGA; EGAS00001000978
DR   GDSC; 683665
DR   GEO; GSM1670075
DR   IARC_TP53; 21487
DR   IGRhCellID; MCCAR
DR   IZSLER; BS TCL 134
DR   LINCS_LDP; LCL-1538
DR   PharmacoDB; MCCAR_885_2019
DR   PubChem_Cell_line; CVCL_1397
DR   Wikidata; Q54904190
RX   DOI=10.1007/0-306-46877-8_4;
RX   Patent=US4434230;
RX   PubMed=2537114;
RX   PubMed=10516762;
RX   PubMed=10936422;
RX   PubMed=12068308;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Group: Patented cell line.
CC   Problematic cell line: Misclassified. Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=10516762).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8083.
CC   Population: Caucasian.
CC   Characteristics: Produces IgG1 kappa.
CC   Doubling time: 19.94 hours (Patent=US4434230).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000160364; Zygosity=Heterozygous (PubMed=12068308; ATCC).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.32%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=66.92%; European, South=32.76% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC; Cosmic-CLP; IZSLER
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,13
ST   D16S539: 11,12
ST   D21S11: 30
ST   D5S818: 11,14
ST   D7S820: 9,13
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 17,18
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   81Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 35
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   Patent=US4434230;
RA   Ritts R.E. Jr.;
RT   "Human nonsecretory plasmacytoid cell line.";
RL   Patent number US4434230, 28-Feb-1984.
//
RX   PubMed=2537114; DOI=10.1182/blood.V73.2.566.566;
RA   Duperray C., Klein B., Durie B.G.M., Zhang X., Jourdan M.,
RA   Poncelet P., Favier F., Vincent C., Brochier J., Lenoir G.M.,
RA   Bataille R.;
RT   "Phenotypic analysis of human myeloma cell lines.";
RL   Blood 73:566-572(1989).
//
RX   PubMed=10516762; DOI=10.1038/sj.leu.2401510;
RA   Drexler H.G., Dirks W.G., MacLeod R.A.F.;
RT   "False human hematopoietic cell lines: cross-contaminations and
RT   misinterpretations.";
RL   Leukemia 13:1601-1607(1999).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//